Filter by content type
Filter by year
Vaccinex Announces Poster Presentations at the 2019 ASCO Annual Meeting
May 15, 2019 - … are summarized below. Title: Preliminary Results From CLASSICAL-Lung, a Phase 1b/2 Study of Pepinemab (VX15/2503) in … are summarized below. Title: Preliminary Results From CLASSICAL-Lung, a Phase 1b/2 Study of Pepinemab (VX15/2503) …
Vaccinex Reports Third Quarter 2020 Financial Results and Provides Corporate Update
November 13, 2020 - … and loss of brain metabolic activity. Non-Small Cell Lung Cancer (NSCLC). CLASSICAL-Lung C linical T rial . The recently completed CLASSICAL-Lung study evaluated pepinemab in combination with …
Vaccinex, Inc. to Present Data on Its Anti-SEMA4D Compound at the American Association for Cancer Research Annual Meeting 2019
March 6, 2019 - … of the posters are below: Title: “Interim results from CLASSICAL-Lung, a Phase Ib/II study of VX15/2503 (pepinemab) in … of the posters are below: Title: “Interim results from CLASSICAL-Lung, a Phase Ib/II study of VX15/2503 (pepinemab) …
Vaccinex, Inc. to Provide Clinical Data on Posters Presented at the 2019 Annual Meeting of the American Association for Cancer Research (AACR)
April 1, 2019 - … : Title: “Interim results from CLASSICAL-Lung, a Phase Ib/II study of VX15/2503 (pepinemab) in … : Title: “Interim results from CLASSICAL-Lung, a Phase Ib/II study of VX15/2503 (pepinemab) …
Vaccinex Announces Award Notice from the Alzheimer’s Association 2020 Part the Cloud Program
November 14, 2019 - … with currently active clinical trials in Non-Small Cell Lung Cancer and Huntington’s disease. Vaccinex is based in … our plans, expectations and objectives with respect to the CLASSICAL-Lung clinical trial, the combination of pepinemab … our plans, expectations and objectives with respect to the CLASSICAL-Lung clinical trial, the combination of pepinemab …
Vaccinex Reports Two Complete Responses in First Three Patients Enrolled in the Phase 1b/2 KEYNOTE-B84 Study of Pepinemab in Combination with KEYTRUDA (pembrolizumab) in Patients with Recurrent or Metastatic Head and Neck Cancer
January 26, 2022 - … none of notable severity Target lesions: metastatic lung lesions (Left 11mm, Right 15mm) Biopsy at Week 5: left … . Vaccinex reported that results of this Phase 1b/2 CLASSICAL-Lung trial showed a 25-33% Overall Response Rate … . Vaccinex reported that results of this Phase 1b/2 CLASSICAL-Lung trial showed a 25-33% Overall Response Rate …
Vaccinex, Inc. Announces Upcoming Presentation at the 2022 American Association for Cancer Research Meeting Updating the Phase 1b Segment of the KEYNOTE-B84 Study of Pepinemab in Combination with KEYTRUDA (pembrolizumab) in Patients with Recurrent or Meta
March 9, 2022 - … . Vaccinex reported that results of the Phase 1b/2 CLASSICAL-Lung trial showed a 25-33% Overall Response Rate (ORR) for … . Vaccinex reported that results of the Phase 1b/2 CLASSICAL-Lung trial showed a 25-33% Overall Response Rate …
Vaccinex Reports Second Quarter 2021 Financial Results and Provides Corporate Update
August 16, 2021 - … Vaccinex announced the publication of results from the CLASSICAL-Lung phase 1b/2 clinical trial in non-small cell lung cancer … Vaccinex announced the publication of results from the CLASSICAL-Lung phase 1b/2 clinical trial in non-small cell …
Vaccinex Reports 2021 Financial Results and Provides Corporate Update
March 31, 2022 - … of patients enrolled in clinical trials, especially the CLASSICAL-Lung and SIGNAL studies. General and Administrative Expenses. … . The Company believes that results of this Phase 1b/2 CLASSICAL-Lung trial supports increased benefit of …
Vaccinex and its Collaborators Present Two Abstracts Related to Pepinemab Combination Immunotherapy Trials at 37th Annual Meeting of Society for Immunotherapy of Cancer
November 10, 2022 - … . Vaccinex reported that results of this Phase 1b/2 CLASSICAL-Lung trial showed a 25-33% Overall Response Rate (ORR) for … . Vaccinex reported that results of this Phase 1b/2 CLASSICAL-Lung trial showed a 25-33% Overall Response Rate …
Pagination
- Previous page
- Page 3
- Next page